Research Reports
Periodic PDF reports on markets, sectors, and capital formation - structured for boards, sponsors, and institutional investors.
Each report examines a specific segment of the growth-stage capital markets. Our team updates facts, data, and transaction observations as conditions move so the version published here reflects our current view. The latest edition of each report appears below, with a brief overview of its contents. For institutional and professional use only.
How year-end deadlines, record dry powder and the exit backlog make Q4 2026 the quarter that decides deal outcomes, and what sellers, sponsors and buyers should do before December 31.
Deal velocity, valuation benchmarks, and capital availability across power, renewables, and midstream assets in North America and the Middle East.
A structured review of raise activity, pricing dynamics, and investor positioning across growth equity, private credit, and structured capital.
How growth-stage biotech and deep-tech companies are positioning for institutional capital across venture crossover, strategic capital, and project finance.
How growth-stage healthcare AI companies are positioning for institutional capital - reimbursement clarity, clinical validation, and enterprise distribution as the new underwriting baseline.
A practical primer on secondary tenders, company-sponsored repurchases, and structured liquidity - when they work, how they are priced, and what boards should prepare.
Reports are published for general information only and do not constitute investment, legal, or tax advice, or an offer of services. For questions on our capabilities, please contact our team.